2 chapters across the catalog
A Mayo Clinic study reveals that African Americans exhibit significantly higher antibody responses to the rubella vaccine compared to other populations. This finding challenges the "one size fits all" approach to immunology and supports the move toward personalized or individualized medicine. The legal classification of vaccines as "biologics" is also noted, which provides manufacturers with indemnification from lawsuits.
Medical researchers suggest that future vaccine dosages may be determined by genetic markers rather than race, potentially requiring different doses for different ethnic groups. There is a critical perspective offered that minority populations are often used as the "baseline" for testing new medical technologies before they are calibrated for wealthier populations. This practice is framed as a form of systemic racism within the pharmaceutical industry.
